SITC 2026 has ended. This guide stays up as the record of who was there. Next: SITC 2027, Nov 3–7, 2027 in National Harbor

National Cancer Institute at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

National Cancer Institute brings 16 presentations to SITC 2026 in Phoenix. Its program centres on adoptive T cell therapies, including engineered receptors and ways to keep tumor-fighting T cells in a long-lived, stem-like state. One concrete item reports interim trial results for T cells engineered to recognize mutant p53 in metastatic solid cancers.

OrganizationSITC 2026 Attendance
Government & non-profit
US federal agency for cancer research and training, part of the National Institutes of Health.
Talk
Thu Nov 5
3:35pm–3:50pm
Talk
Thu Nov 5
2:35pm–2:45pm
Session
Fri Nov 6
8:00am–8:05am
Presidential Welcome
Poster
Fri Nov 6
12:15–1:45pm
5:30–7pm
Session
Fri Nov 6
3:55pm–5:30pm
Oral Abstract Session 2
  1. 3:58pm–4:13pmCTH-401: Allogeneic iPSC-derived CAR-NK cells for the treatment of ovarian cancerCartherics
  2. 4:13pm–4:28pmMyeloid-selective P-LNP enables in vivo engineering of GPC3-targeted CAR macrophages, resulting in robust tumor control and antitumor macrophage reprogrammingUnited Immunity
  3. 4:28pm–4:43pmPTPN22 editing enhances CAR-NK cell persistence and antitumor activity under tumor-associated inflammatory stressChonnam National University
  4. 4:43pm–4:58pmCD4+ T cell-intrinsic IL-12 signaling mediates inflammatory tumor control with reduced toxicityFred Hutchinson Cancer Center
  5. 4:58pm–5:13pmAdoptive transfer of T cells engineered with mutant p53-specific TCRs for the treatment of metastatic solid epithelial cancers: interim report of ongoing phase II clinical trialNational Cancer Institute
  6. 5:13pm–5:28pmMacrophage-derived lipid transfer enables metabolic buffering and chemotherapy resistance in glioblastomaMayo Clinic
Poster
Sat Nov 7
12–1:30pm
6:40–8:10pm
Session
Sun Nov 8
8:15am–9:40am
Presidential Session
  1. 8:20am–8:35amSlit2–Robo1/2 signaling orchestrates a lymphovascular–myeloid axis that limits T cell priming and drives immunotherapy resistanceNYU Langone Health
  2. 8:35am–8:50amDual targeting of GARP on tumor and regulatory T cells with bispecific T cell engagers for effective cancer immunotherapyThe Ohio State University
  3. 8:50am–9:00amExpert DiscussantUC San Diego
  4. 9:00am–9:15amCholesterol-Dependent Glycolytic Shunting Through the ABCA1–HMOX1 Axis Sustains Immunosuppressive Myeloid Fitness in GlioblastomaStanford University
  5. 9:15am–9:30amTargeting a CD36-Dependent Macrophage Immunometabolic Program Enhances PARP Inhibitor Response in BRCA-Associated TNBCBrigham and Women's Hospital
  6. 9:30am–9:40amExpert DisucussantUniversity of Pittsburgh

Explore the full SITC 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Phoenix. Leave your work email and we’ll be in touch.

Privacy

Download the full SITC 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at National Cancer Institute

Tell us what you sell and we’ll find the people at National Cancer Institute most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction